Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19

4Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients.

Cite

CITATION STYLE

APA

Kombarova, S. Y., Aleshkin, A. V., Novikova, L. I., Bochkareva, S. S., Zatevalov, A. M., Mekhtiev, E. R., … Karaulov, A. V. (2022). Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19. Bulletin of Experimental Biology and Medicine, 173(6), 734–739. https://doi.org/10.1007/s10517-022-05620-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free